Indoco Remedies Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/29qy0rkdlpb94xz0gulmi5vw.pdf

Key Takeaways


Domestic Business: The Acute Drag

Aditi Panandikar: "this has been a year for Indoco of many hits and a few misses and since the few misses seem to overawe our financial performance, I would like..."

International Business: Europe & Emerging Markets Lead

Sundeep Bambolkar: "At least as far as U.S. market is concerned, knowledgeable sources say that prices have bottomed out. So from here on, things should only improve."

U.S. Business: Regulatory Clean-Up & Model Shift

Sundeep Bambolkar: "as of 2 hours ago, happy to share that, our API Kilo Lab manufacturing facility and Indoco Analytical Services testing lab has successfully cleared the U.S. FDA audit with 0483s"

Strategic Shift: From Acute to Chronic


Margins & Cost Structure

Aditi Panandikar: "I feel very confident that we should be able to bounce back to 17% to 18% over the next few"

Guidance & Commitments

CommitmentSpecificsTimeline
Europe revenue growthAround 15% to 20% growthFY25
Manufacturing efficiency impactMargin improvement from international efficiency planEnd of Q1 FY25 or halfway through Q2 FY25
U.S. product approvals3 to 4 approvals, largely oral solidsFY25
CapexWithin about ₹250 crFY25
R&D investment5% to 6% of salesOngoing
EBITDA margin recoveryBounce back to 17% to 18%Over the next few years
Emerging markets quarterly run rateSustainable at around ₹50 cr to ₹55 crOngoing
No MR additionsZero medical representative additionsFY25
U.S. FDA reinspectionComplete last update to FDA, then FDA plans visit dateUpdate by July/August; visit date thereafter
Combigan/Brinzolamide line refurbishmentRefurbishment completeLate August or mid-September
Paracetamol order revivalOrders accelerateWithin 15 days to 1 month

Key Metrics

MetricQ4 FY24
Net revenue₹435.1 cr, +1.7% YoY vs ₹428 cr
Net revenue (full year FY24)₹1,761.9 cr, +7.6% YoY vs ₹1,638.1 cr
EBITDA to net sales13.2% at ₹57.4 cr vs 15% at ₹64.2 cr
EBITDA to net sales (full year FY24)14.6% at ₹258 cr vs 17.4% at ₹284.9 cr
PAT to net sales8.6% at ₹37.6 cr vs 5.9% at ₹25.4 cr
PAT to net sales (full year FY24)6.6% at ₹116.6 cr vs 8.6% at ₹141.4 cr
EPS₹4.07 vs ₹2.75
EPS (full year FY24)₹12.64 vs ₹15.32
Domestic formulation revenue₹191.1 cr, +3.6% YoY vs ₹184.5 cr
International formulation revenue₹214 cr, -1% YoY vs ₹216.2 cr
US business revenue₹67.5 cr vs ₹71.3 cr
Europe revenue₹76.4 cr vs ₹82.1 cr; full year FY24 ₹277 cr
Emerging markets revenue₹68.2 cr, +29.1% YoY vs ₹52.8 cr
API business revenue₹21.7 cr vs ₹22.8 cr; full year FY24 ₹126 cr, +79% YoY
AnaCipher CRO and Indoco Analytical Solutions revenue₹8.3 cr, +85% YoY vs ₹4.5 cr
Paracetamol revenue₹37 cr vs ₹46 cr in Q4 FY23 and ₹30 cr in Q3 FY24
Remediation expenses~₹5 cr per quarter
Micro Labs plant utilization~50%, down from in excess of 70% previously due to lower paracetamol orders
Europe products sold10 products currently; 4 new launches planned for next year
Emerging markets CAGR (last 4 years)24%
Sensodent K growth~16%
Febrex Plus degrowth (full year FY24)10%
R&D spend5% to 6% of sales
Capex plan (FY25)~₹250 cr
US FDA audit outcome (API Kilo Lab and Indoco Analytical Services)Cleared with 483s